Brad C. Klein, MD
Dr. Klein graduated with highest honors with dual majors in biology and psychology from Rutgers College, Rutgers University. He received his medical degree from Jefferson Medical College (now Sidney Kimmel Medical College) concurrently with a Master’s in Business Administration in Health and Medical Sciences Administration from Widener University. He completed his neurology residency and headache fellowship at Thomas Jefferson University Hospital.
He is a board-certified neurologist with additional certification in Headache Medicine and Electromyography. Dr. Klein joined Abington Neurological Associates in 2008 and also serves as the Medical Director of the Abington Headache Center and is a Clinical Associate Professor in the Department of Neurology at Sidney Kimmel Medical College, Thomas Jefferson University Hospital.
Dr. Klein is actively involved in neurological clinical trials and works on state and national levels to advocate for patients with neurological illnesses. He is the founder and past President of the Pennsylvania Neurological Society, current member of the Governor’s Pennsylvania Healthcare Cost Containment Council, and serves in a number of national leadership roles within the American Headache Society as well as the American Academy of Neurology (AAN), including as the Chair of Medical Economics and Practice Committee in addition to the Board of Directors for the AAN. He has also been named a Top Doc by Philadelphia Magazine multiple years in a row.
As a national key opinion leader, Dr. Klein has also collaborated with multiple companies, including Alder Pharmaceuticals, Allergan, Amgen, Assertio, Biohaven, Depomed, Eli Lilly, GlaxoSmithKline, MAP Pharmaceuticals, Merck, Nautilus Neurosciences, Promius, Teva, US Worldmeds, and Zogenix Pharmaceuticals to help bring new treatments to patients and increase awareness of neurological illnesses. In this capacity, Dr. Klein has served as a research investigator, consultant, and/or directly provided medical education to providers and/or patients to further improve neurological care in his community as well as across the country.